UCSF announced that it has concluded another drug development deal with a Big Pharma company - this time with Pfizer. The deal is worth up to $85 M to the University. Pfizer will set up joint laboratories on campus, combining its knowledge of drug development with the basic research expertise at UCSF.
For its $85 M, Pfizer will share the ownership rights to new drugs with the University. UCSF researchers would be allowed to publish their research findings in academic journals and share the knowledge with peers. See Xconomy.
Earlier this year, UCSF annoounced an agreement with Genentech to collaborate on the development of drugs for neurodegenerative diseases. Bayer also agreed to move into its Mission Bay R&D Center to collaborate on hematology, cardiology, oncology and women's health applications. See here for other pharma-university deals struck this year.
There has been an uptick in these type of research collaborations as Big Pharma attempts to revitalize its collective pipeline. Recent reports have indicated that more novel therapeutics are being discovered in university settings - particularly for biotech drugs, and rare/orphan disease targets. See here.
Posted by Bruce Lehr November 16th 2010.